Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced that chief executive...
-
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at...
-
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel...
-
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster...
-
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development developing precision novel therapeutics for central nervous system (CNS) diseases using...
-
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
-
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
-
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
-
BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
-
BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel precision therapeutics for central nervous system...